GlassScriptPhysician profile
Wilson L Wang
NPI 1740203603
$4,886.18
in general payments reported to CMS, 2019-2025
26 companies · $202 in 2025
The $202 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $892 · 2020: $747 · 2021: $830 · 2022: $796 · 2023: $1,246 · 2024: $173 · 2025: $202.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,621.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,621.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,160.72 | 2019-2023 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $570.43 | 2019-2024 | Lifevest |
| Amgen INC. | $530.80 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $460.38 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $393.31 | 2019-2025 | Camzyos, Eliquis |
| Amarin Pharma, INC. | $276.29 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $249.20 | 2020-2023 | Farxiga |
| Chiesi USA, INC. | $166.09 | 2020-2022 | |
| Pfizer INC. | $149.97 | 2020-2023 | |
| Esperion Therapeutics, INC. | $146.94 | 2021-2023 | Nexletol |
| Alexion Pharmaceuticals, INC. | $122.09 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $107.53 | 2022-2023 | Jardiance |
| Merck Sharp & Dohme LLC | $91.73 | 2021-2023 | Verquvo |
| Bayer Healthcare Pharmaceuticals INC. | $90.83 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $70.72 | 2019-2023 | Evkeeza |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals, LTD. | $45.87 | 2023 | Arcalyst |
| Sanofi-Aventis U.S. LLC | $40.13 | 2019 | |
| Cvrx, INC. | $36.39 | 2023 | Barostim Neo System |
| Abbott Laboratories | $35.17 | 2019 | |
| Abiomed | $35.15 | 2022 | |
| Boston Scientific Corporation | $25.13 | 2021 | |
| Kiniksa Pharmaceuticals International, Plc | $17.12 | 2024 | Arcalyst |
| Arbor Pharmaceuticals, INC. | $17.00 | 2020 | |
| Baxter Healthcare | $16.95 | 2022 | |
| Kestra Medical Technology Services, INC. | $15.38 | 2022 | |
| Mallinckrodt Hospital Products INC. | $14.86 | 2024 | Terlivaz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wilson Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.